洛替拉纳(Lotilaner) - 药物靶点：GluCls_在研适应症：睑缘炎，蠕形螨感染，睑板腺功能障碍_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Siegfried 295224、SMisoxam、AHC 2224920

+ [7]

靶点

GluCls

作用机制

GluCls抑制剂(谷氨酸门控氯离子通道抑制剂)

治疗领域

眼部疾病感染皮肤和肌肉骨骼疾病+ [1]

在研适应症

睑缘炎蠕形螨感染睑板腺功能障碍+ [1]

非在研适应症

疟疾

原研机构

Tarsus Pharmaceuticals, Inc.

在研机构

NextPharma Oy

Tarsus Pharmaceuticals, Inc.LianBio

非在研机构-

最高研发阶段批准上市

首次获批日期

美国 (2023-07-24),

睑缘炎

最高研发阶段(中国)临床3期

特殊审评-

登录后查看首次获批时间轴

结构

分子式C20H14Cl3F6N3O3S

InChIKeyHDKWFBCPLKNOCK-SFHVURJKSA-N

CAS号1369852-71-0

关联

21

项与洛替拉纳相关的临床试验

NCT06182358 / Recruiting临床4期

Randomized Controlled Trial to Evaluate the Impact of XDEMVY® on Demodex Blepharitis in Soft Contact Lens Wearers

To compare the efficacy of XDEMVY ophthalmic drop to its vehicle control for the treatment of Demodex blepharitis and its impact on the soft contact lens wearing experience.

开始日期2023-12-27

申办/合作机构

Tarsus Pharmaceuticals, Inc.

NCT05838170 / Completed临床2期

A Phase 2, Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety, Tolerability, and Efficacy of TP-04 in Participants With Papulopustular Rosacea

This study is being done to evaluate the safety, tolerability, and efficacy of the study drug, TP-04, in participants with papulopustular rosacea (PPR).

开始日期2023-03-01

申办/合作机构

Tarsus Pharmaceuticals, Inc.

NCT05720364 / Completed临床1期

A Phase 1, Open-Label, Randomized, Single-Dose, Parallel-Group Study to Evaluate the Food Effect on the Pharmacokinetics of TP-05 Under Fed and Fasted Conditions in Healthy Participants

A Phase 1, Open-Label, Randomized, Single-Dose, Parallel-Group Study to Evaluate the Food Effect on the Pharmacokinetics of TP-05 under Fed and Fasted Conditions in Healthy Participants.

开始日期2023-01-19

申办/合作机构

Tarsus Pharmaceuticals, Inc.

100 项与洛替拉纳相关的临床结果

登录后查看更多信息

100 项与洛替拉纳相关的转化医学

登录后查看更多信息

100 项与洛替拉纳相关的专利（医药）

登录后查看更多信息

123

项与洛替拉纳相关的文献（医药）

Ocular immunology and inflammation

Efficacy and Safety of Lotilaner Ophthalmic Solution 0.25% in the Treatment of Demodex Blepharitis: A Systematic Review and Meta-Analysis

Review

作者: Elganady, Asmaa ; Abo Zeid, Mohamed ; Abu Serhan, Hashem ; Elrosasy, Amr ; Abbas, Ahmed W ; Rhab, Ahmed Elhadi

PURPOSE:

To evaluate the safety and efficacy of Lotilaner ophthalmic solution 0.25% in the treatment of demodex blepharitis.

METHODS:

PubMed, Web of Science, Scopus, and Embase databases were searched. RCTs comparing lotilaner with placebo or any other standard treatments were included. Outcomes of mean collarette grade (MCG), mite density (Md), meaningful collarette reduction (MCR), mite eradication (ME), were pooled as mean difference (MD), and the outcomes of erythema cure (EC), collarette cure (CC) adverse events (AE) as risk ratio (RR) with their 95% confidence interval (CI) between the two groups from baseline to the endpoint. Review Manager (Version 5.4.1) software was used to conduct all statistical analyses.

RESULTS:

Four RCTs (947 patients) were included in this study. The overall effect favored the lotilaner group in terms of mean collarette grade upper lid (MD -0.99, 95% CI [-1.26, -0.72]), MCG lower lid (MD -0.57, 95% CI [-1.03, -0.11]), Md (MD -1.13, 95% CI [-1.47, -0.79]), MCR (MD 2.07, 95% CI [2.27, 3.21]), ME (MD 3.46, 95% CI [2.96, 4.04]). EC (RR 3.16, 95% CI [2.18 to 4.59]) and CC (RR 4.17, 95% CI [2.97 to 5.85]). No significant difference between the two groups in terms of AE (RR 1.25, 95% CI [0.75 to 2.06]). However, these findings are limited by significant heterogeneity in some of the reported outcomes.

CONCLUSIONS:

Our findings show that lotilaner might effectively treat Demodex blepharitis. However, further RCTs with larger and more diverse populations are needed to confirm these findings as some outcomes show significant heterogeneity.

2023-11-01·Drugs

Lotilaner Ophthalmic Solution 0.25%: First Approval

Review

作者: Syed, Yahiya Y

Lotilaner ophthalmic solution 0.25% (XDEMVY™), a gamma-aminobutyric acid-gated chloride channel (GABA-Cl) inhibitor selective for mites, is being developed by Tarsus Pharmaceuticals for the treatment of Demodex blepharitis and meibomian gland dysfunction in patients with Demodex lid infestation (Demodex-induced meibomianitis). On 24 July 2023, lotilaner ophthalmic solution 0.25% received its first approval in the USA for the treatment of Demodex blepharitis. The agent is also currently in phase 3 development for Demodex blepharitis in China and phase 2 development for Demodex-induced meibomianitis in the USA. This article summarizes the milestones in the development of lotilaner ophthalmic solution 0.25% leading to this first approval for the treatment of Demodex blepharitis in the USA.

2023-11-01·The American journal of tropical medicine and hygiene

Canine Systemic Insecticides Fluralaner and Lotilaner Induce Acute Mortality of Triatoma gerstaeckeri, North American Vector of the Chagas Disease Parasite

Article

作者: Hamer, Gabriel L ; Zecca, Italo B ; Hamer, Sarah A ; Busselman, Rachel E

ABSTRACT.:

Chagas disease is a health concern for humans and animals across the Americas, and control options targeting the triatomine vectors of Trypanosoma cruzi, the causative agent of Chagas disease, are limited. Host-targeted interventions may be a useful and underused tool in controlling the spread of T. cruzi from vectors to hosts. Domestic dogs are known to be key bloodmeal hosts for triatomines as well as T. cruzi reservoirs and may be an effective and practical target for host-targeted insecticide deployment. We hypothesized that treating dogs with commercially available systemic insecticides (labeled for flea and tick control) would result in mortality of triatomines after consuming treated blood. We enrolled 16 privately owned dogs into five treatment groups to receive either fluralaner (Bravecto) or lotilaner (Credelio), alone or in combination with ivermectin. Blood from dogs before the initiation of treatment served as controls. Blood was collected 0, 7, 30, 45, and 90 days after the initial canine insecticide treatment and fed to 10 Triatoma gerstaeckeri nymphs through a membrane feeder, and survival was tracked daily for 7 days and weekly thereafter. All triatomines in the control and ivermectin groups survived the initial period, with no significant difference in long-term survival. In contrast, 99.7% of triatomines that fed on blood from dogs treated with either fluralaner or lotilaner died within 3 days. Although the impact of canine treatment on suppressing vector populations is unknown, fluralaner and lotilaner appear to be a compelling option for an integrated vector management approach to triatomine control.

103

项与洛替拉纳相关的新闻（医药）

2024-06-12

·E药经理人

百济“神秘”大股东，狂“买”中国创新药！这家对冲基金有何来头？

Seagen曾经最大股东，百济神州第二大股东，康方合作伙伴Summit第四大股东，如今所投资的海思科海外合作方再登IPO舞台，仅有25名员工却管理250亿美元，这家总资产20年翻百倍的海外对冲基金有何来头？撰文| Erin 编辑| 润屿顿河近日，海思科TYK2抑制剂ESK-001出海的合作伙伴美国生物技术公司Alumis提交了在纳斯达克的IPO申请，募集资金用以支持ESK-001的III期临床。在此之前，Alumis已凭借ESK-001完成了多轮过亿美元融资，其中B轮融资约3亿美元，投资方包括Matrix Capital、Baker Brothers等知名投资机构。值得一提的是，投资方之一的对冲基金Baker Brothers，其投资标的与中国公司有着千丝万缕的关系。上个月，Baker Brothers刚刚投资了康方生物的合作伙伴Summit，成为其第四大股东。此外，Baker Brothers还是百济神州的十大股东之一。而这家隐匿于生物技术公司背后的神秘“大佬”，眼光颇为独到，核药明星Bicycle、推出全球首款NASH新药的Madrigal都在持仓名单中。不仅如此，Baker Brothers还曾是ADC先驱Seagen的最大股东，昔日Seagen被辉瑞收购，为Baker Brothers带来了80亿美元的收益。盘点这家对冲基金在生物技术公司上的投资，不可谓一段传奇。2003年时总资产为2.5亿美元，但到了2023年，其资产已增百倍至257亿美元。这家对冲基金的独到眼光，究竟是怎样炼成的？又为何狂“买”中国药企创新资产？重仓中国创新药的海外基金，还有谁？长期持仓，高收益，总资产20年增百倍 Baker Brothers自创立以来，就专注于生物技术公司的投资。多年来，这家对冲基金几乎是生物技术超级爆款的“掘金队”，且因对生物技术赛道“长期持仓，获得高收益”的独到眼光而闻名，曾重仓的Seagen、Mirati、Alexion等生物技术公司，纷纷被MNC并购，更是重复验证了这一能力。 Baker Brothers在近年最出名的一次事件，莫过于在2023年辉瑞收购Seagen后，一下子获得了80亿美元的高额收益。据悉，Baker Brothers自2003年就投资了当时还名叫Seattle Genetics的Seagen，此后持续加仓，到了2005年，Baker Brothers的创始人之一Felix Baker就成为了Seattle Genetics的首席独立董事。截至辉瑞完成收购前，Baker Brothers是Seagen的最大股东，持股比例超过25%。这场长达20年的“陪跑”，也为Baker Brothers带来了80亿美元的收益。投资Seagen的案例并非Baker Brothers首次打响名号。 2015年，艾伯维以每股261.25美元、总额210亿美元收购了Pharmacyclics，获得了伊布替尼。彼时，Pharmacyclics是Baker Brothers最大的持仓，持有约900万股Pharmacyclics股票，总价值超过12亿美元。此后，Baker Brothers所投资的Alexion、ChemoCentryx、Mirati等相继被AZ、安进、BMS等MNC收入囊中。Baker Brothers的总资产也水涨船高，截至2023年年底，其总资产高达257亿美元，相较于2003年2.5亿美元，翻了100倍。值得一提的是，Baker Brothers虽然目前管理着超过250亿美元的资产，但其员工总数仅有25人，且一直保持神秘，迄今甚至连官网都没有。但Baker Brothers能获得如此高收益，离不开“人”的因素。据悉，Baker Brothers的创始人是Julian Baker、Felix Baker两兄弟，2000年成立之时的主要资金来自美国财团Tisch家族，之后还引入了耶鲁捐赠基金会。创始人两兄弟分别拥有斯坦福大学免疫学博士学位和瑞士信贷第一波士顿银行的私募部门工作背景，“生物技术+投资”两大专业背景的组合为他们在投资中建立了独特眼光，而两兄弟在投资后通常会加入被投公司的董事会，其专业背景也能保障为被投公司做好长期的投后管理。当然，其投资标的屡屡被MNC青睐，或许也与两兄弟的投后管理不无关系。根据Baker Brothers所提交给SEC的文件，这家对冲基金目前持有86只股票，前五大持股占其总资产的68%，这显示出“高度集中投资”的特点。而Baker Brothers持有的投资组合十分有意思：几乎都是生物技术各个领域的佼佼者。最大持仓的Incyte，已经是全球知名制药公司，还是JAK抑制剂的先驱，已获批8款创新药；第三持仓的Acadia Pharmaceuticals，也是全球中枢神经系统疾病领域的头部公司，多个产品都是全球首个且唯一的疗法；第四持仓的Madrigal Pharmaceuticals，研发出了全球首款NASH疗法；此外，Baker Brothers所持仓的Bicycle、Kymera、Immatics等公司也分别是核药、蛋白降解、TCR-T细胞疗法领域的明星公司，并被诺华、赛诺菲、BMS等MNC青睐。推荐阅读 * AZ、诺华密集抄底中国Biotech！罗氏开年4笔，BMS一月许出265亿美元，MNC并购背后的权谋 * 溢价154%！AZ打响第一枪！本土CAR-T四小龙之一“卖身”MNC，下一个是谁？重仓中国创新药的海外基金除了具有较高的被并购潜力外，Baker Brothers的投资标的，更与中国创新药关系非常紧密。 Baker Brothers的第二大持仓，正是中国的创新药“一哥”百济神州。截至今年4月19日，Baker Brothers持有百济神州10.2%的普通股，是百济的十大股东之一。 ▲来源：百济神州2024年年度股东大会会议资料而Baker Brothers最大持仓的Incyte，分别与信达、康哲、诺诚健华都有合作。此外，在亘喜生物被AZ收购前，Baker Brothers也是其股东之一。再加上其投资的海思科合作伙伴Alumis、康方合作伙伴Summit，Baker Brothers几乎可以称得上中国创新药出海背后神秘的“最大买家”之一。与Baker Brothers和中国创新药的“隐形”关系不同，海外基金RTW Investments、Perceptive Advisors则直接参与了中国Biotech公司的孵化。例如在2019年，由Perceptive Advisors孵化的联拓生物成立，并于2021年在纳斯达克上市，主要专注于将欧美的创新药引入中国，成立短短几年，联拓生物就建立了Mavacamten、TP-03、NBTXR3、infigratinib（英菲格拉替尼）多个管线，横跨心血管、眼科、肿瘤、炎症四大领域。虽然最终以联拓生物关停为结局，但也代表着一次国外基金到中国孵化Biotech的实践。而与Perceptive Advisors不同，RTW Investments与中国创新药的关系更加紧密，不仅孵化了箕星药业，还参与了恒瑞GLP-1的授权出海。 RTW所孵化的箕星药业也专注于将海外创新药带入中国，通过这条路径，箕星药业目前建立了心血管领域和眼科疾病领域的多个产品管线，并已经有9个临床后期阶段在研产品。值得注意的是，箕星药业还在今年1月获得了拜耳与RTW的D轮融资，拜耳集团处方药事业部全球执行副总裁兼中国区总裁、拜耳集团大中华区总裁周晓兰更是加入到了箕星董事会。另外，今年5月，恒瑞的三款GLP-1产品授权给刚刚成立不久的美国Hercules公司。Hercules公司恰恰是由贝恩资本、Atlas Ventures、RTW、Lyra资本联合出资创立。除了Perceptive Advisors和RTW外，其实国内还有很多由海外基金参与孵化的Biotech，如信瑞诺、经久生物、维亚臻生物等，并且已经诞生了一笔海外基金成功退出的孵化：今年1月，诺华宣布收购信瑞诺医药，并将其将整体整合入诺华中国。据悉，信瑞诺成立于2021年，专注于肾脏疾病及相关治疗领域，由海外生物技术公司Chinook Therapeutics与鼎丰生科资本、Frazier Healthcare Partners等投资机构共同设立。其中，Chinook通过技术入股，以2个药(atrasentan、BION-1301)的大中华区权益换取合资公司信瑞诺50%A轮优先股，投资机构投资4000美元获得另外50%股份。而在2023年，诺华收购了Chinook。因此，诺华再收购信瑞诺的交易，也被行业解读为诺华“不舍” atrasentan和zigakibart两款重磅产品剩下50%的中国权益。回复“V”，了解电子期刊详情精彩推荐 CM10 | 集采 | 国谈 | 医保动态 | 药审 | 人才 | 薪资 | 榜单 | CAR-T | PD-1 | mRNA | 单抗 | 商业化 | 国际化｜猎药人系列专题 | 出海启思会 | 声音·责任 | 创百汇 | E药经理人理事会 | 微解药直播 | 大国新药 | 营销硬观点 | 投资人去哪儿 | 分析师看赛道 | 药事每周谈 | 医药界·E药经理人 | 中国医药手册创新100强榜单 | 恒瑞 | 中国生物制药 | 百济 | 石药 | 信达 | 君实 | 复宏汉霖｜翰森 | 康方生物 | 上海医药 | 和黄医药 | 东阳光药 | 荣昌 | 亚盛医药 | 齐鲁制药 | 康宁杰瑞 | 贝达药业 | 微芯生物 | 复星医药｜再鼎医药｜亚虹医药跨国药企50强榜单 | 辉瑞 | 艾伯维 | 诺华 | 强生 | 罗氏 | BMS | 默克 | 赛诺菲 | AZ | GSK | 武田 | 吉利德科学 | 礼来 | 安进 | 诺和诺德 | 拜耳 | 莫德纳 | BI | 晖致 | 再生元

并购临床3期抗体药物偶联物IPO

2024-05-29

·GlobeNewswire-Health Care

Tarsus to Participate in Upcoming Investor Conferences

IRVINE, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that management will participate in the following conferences: William Blair Growth Stock Conference Jeff Farrow, Chief Financial and Chief Strategy Officer, will participate in an in-person fireside chat on Tuesday, June 4, 2024, at 1:20 p.m. PT / 4:20 p.m. ET Jefferies Global Healthcare Conference Jeff Farrow, Chief Financial and Chief Strategy Officer, and Aziz Mottiwala, Chief Commercial Officer, will participate in an in-person fireside chat on Wednesday, June 5, 2024, at 12 p.m. PT / 3 p.m. ET Goldman Sachs Global Healthcare Conference Bobak Azamian, M.D., Ph.D., Chief Executive Officer and Chairman, and Jeff Farrow, Chief Financial and Chief Strategy Officer, will participate in an in-person fireside chat on Monday, June 10, 2024, at 11 a.m. PT / 2 p.m. ET Live webcasts and additional information about the webcasts can be accessed on the events section of the Tarsus website. Replays of the webcasts will be available on the Tarsus website within 48 hours and will be archived for a limited time. About Tarsus Pharmaceuticals, Inc.Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care, dermatology and infectious disease prevention. XDEMVY® (lotilaner ophthalmic solution) 0.25% is FDA approved in the United States for the treatment of Demodex blepharitis. Tarsus is also developing TP-03 as an investigational therapy for the treatment of Meibomian Gland Disease, TP-04 for the treatment of rosacea and TP-05 as an oral tablet for the prevention of Lyme disease, all of which are in Phase 2. Contacts:Media Contact:Adrienne KempSr. Director, Corporate Communications(949) 922-0801akemp@tarsusrx.com Investor Contact:David NakasoneHead of Investor Relations(949) 620-3223DNakasone@tarsusrx.com

上市批准临床2期

2024-05-09

·GlobeNewswire-Health Care

Tarsus to Participate in Fireside Chat at the 2024 Bank of America Healthcare Conference

IRVINE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Bobak Azamian, M.D., Ph.D., Chief Executive Officer and Chairman, will participate in an in-person fireside chat at the 2024 Bank of America Healthcare Conference taking place in Las Vegas, NV, on Wednesday, May 15, at 1:55 p.m. PT / 4:55 p.m. ET. A live webcast and additional information about the presentation can be accessed on the events section of the Tarsus website. The replay will be available on the Tarsus website within 48 hours and will be archived for a limited time. About Tarsus Pharmaceuticals, Inc.Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care, dermatology and infectious disease prevention. XDEMVY® (lotilaner ophthalmic solution) 0.25% is FDA approved in the United States for the treatment of Demodex blepharitis. Tarsus is also developing TP-03 as an investigational therapy for the treatment of Meibomian Gland Disease, TP-04 for the treatment of rosacea and TP-05 as an oral tablet for the prevention of Lyme disease, all of which are in Phase 2. Media Contact:Adrienne KempSr. Director, Corporate Communications(949) 922-0801akemp@tarsusrx.com Investor Contact:David NakasoneHead of Investor Relations(949) 620-3223DNakasone@tarsusrx.com

上市批准临床2期

100 项与洛替拉纳相关的药物交易

登录后查看更多信息

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
睑缘炎	美国	Tarsus Pharmaceuticals, Inc.	2023-07-24

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
蠕形螨感染	临床3期	中国	LianBio	2022-10-23
莱姆病	临床2期	美国	Tarsus Pharmaceuticals, Inc.	2023-03-14
睑板腺功能障碍	临床2期	美国	Tarsus Pharmaceuticals, Inc.	2022-08-03
疟疾	临床1期	美国	Tarsus Pharmaceuticals, Inc.	2021-06-18

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05387083 (Corporate Publications) 人工标引	临床2期	莱姆病	-	lotilaner high dose	範獵鬱網鑰簾鹽選齋壓(築餘選襯憲壓糧艱衊網) = 艱廠獵餘顧築製鏇網繭膚鬱窪蓋壓壓鏇膚夢膚 (餘築襯觸構繭艱鹽蓋顧, 1.4) 更多	积极	2024-02-22
				lotilaner low dose	範獵鬱網鑰簾鹽選齋壓(築餘選襯憲壓糧艱衊網) = 積廠願製願壓窪鏇獵築膚鬱窪蓋壓壓鏇膚夢膚 (餘築襯觸構繭艱鹽蓋顧, 6.3) 更多
NCT04784091 (CTgov)	临床3期	睑缘炎 \| 蠕形螨感染	412	TP-03 (Active)	範願鹹鹽憲襯築願選窪(蓋廠壓襯夢選夢窪範簾) = 願繭鏇糧獵繭膚範壓鹽廠襯遞艱鹽製鏇鬱廠獵 (鏇鹽膚糧衊鹹範構壓築, 網製製憲衊遞鏇願鑰膚 ~ 艱願繭壓餘艱齋衊簾艱) 更多	-	2023-12-21
				TP-03 Vehicle (Control)	範願鹹鹽憲襯築願選窪(蓋廠壓襯夢選夢窪範簾) = 鹹襯顧鑰簾觸襯蓋襯蓋廠襯遞艱鹽製鏇鬱廠獵 (鏇鹽膚糧衊鹹範構壓築, 蓋齋鏇壓簾鹽醖蓋範窪 ~ 遞選憲鏇觸醖鹹獵憲製) 更多
NCT04475432 (CTgov)	临床2/3期	蠕形螨感染 \| 睑缘炎	421	TP-03, 0.25% (Active)	壓襯顧鬱構糧觸鏇選觸(醖窪淵簾遞觸鹹醖構顧) = 繭壓膚獵膚壓製繭鹽觸餘鹽衊衊選範獵遞膚醖 (鹽鏇鬱鑰顧醖憲廠構夢, 鏇鹽夢鬱襯獵製糧糧鑰 ~ 艱構簾觸鏇壓製淵窪鹽) 更多	-	2023-12-21
				TP-03 Vehicle (Control)	壓襯顧鬱構糧觸鏇選觸(醖窪淵簾遞觸鹹醖構顧) = 醖憲築壓遞簾醖廠鹹築餘鹽衊衊選範獵遞膚醖 (鹽鏇鬱鑰顧醖憲廠構夢, 遞繭醖觸膚襯衊選夢壓 ~ 醖餘鬱壓鬱蓋齋觸範範) 更多
CTR20220726 \| NCT05629390 (LIBRA, GlobeNewswire) 人工标引	临床3期	蠕形螨感染	-	TP-03	餘廠廠壓窪願淵網鬱鑰(鬱衊觸膚範窪鹹醖顧憲) = Results demonstrated statistically significant mite eradication in patients 鏇顧襯廠襯築製積簾衊 (構蓋觸遞獵膚願簾蓋獵 ) 更多	积极	2023-10-30
				vehicle
Saturn-2 (FDA) 人工标引	N/A	睑缘炎	833	XDEMVY	壓觸夢壓繭築範範廠糧(糧鹹夢網艱顧廠積鏇艱) = The most common ocular adverse reaction observed in controlled clinical studies with XDEMVY was instillation site stinging and burning which was reported in 10% of patients. Other ocular adverse reactions reported in less than 2% of patients were chalazion/hordeolum and punctate keratitis. 齋憲餘淵襯夢窪膚壓糧 (鑰顧壓襯鑰淵醖襯繭窪 ) 更多	积极	2023-07-24
				Vehicle
NCT04475432 (Saturn-1, Pubmed)	临床2/3期	蠕形螨感染	421	Lotilaner ophthalmic solution, 0.25%	餘遞膚鏇觸繭鏇鹹選構(襯鑰繭獵襯壓構蓋窪憲) = All ocular adverse events in the study group were mild, with the most common being instillation site pain. 壓簾廠淵獵觸獵鏇糧構 (淵膚築齋艱廠襯選願築 )	积极	2022-08-11
				Vehicle without lotilaner
Saturn-2 (GlobeNewswire) 人工标引	临床3期	蠕形螨感染	412	Lotilaner	簾獵蓋壓壓繭範構齋壓(艱艱網膚艱鏇襯觸鹽繭) = 願獵遞構網鏇鑰襯製淵積積鹽艱膚糧齋鬱憲製 (範鑰築襯窪築範夢築積 ) 更多	积极	2022-05-02
				Placebo	簾獵蓋壓壓繭範構齋壓(艱艱網膚艱鏇襯觸鹽繭) = 築願網顧範廠繭顧鹹衊積積鹽艱膚糧齋鬱憲製 (範鑰築襯窪築範夢築積 ) 更多
ARVO2021	临床2期	蠕形螨感染	-	Lotilaner Ophthalmic Solution 0.25%	遞醖鏇獵膚醖淵積壓積(繭鏇廠淵簾糧獵遞觸廠) = 願鑰艱鏇顧膚醖憲範鬱積壓餘壓構繭鬱網壓鑰 (顧繭顧願願鏇觸醖淵觸 ) 更多	-	2021-06-01
				Vehicle	遞醖鏇獵膚醖淵積壓積(繭鏇廠淵簾糧獵遞觸廠) = 網鹹積壓觸鹹顧壓壓築積壓餘壓構繭鬱網壓鑰 (顧繭顧願願鏇觸醖淵觸 ) 更多
Mars Study (ARVO2020)	N/A	-	15	TP-03 0.25%	鹹築願醖襯獵網網餘繭(觸範鹹淵獵網齋醖鏇衊) = No treatment-related adverse events were reported 艱鬱鹹構製淵範範遞襯 (鬱艱鏇糧齋糧鹹鑰齋糧 )	积极	2020-06-01